S. 4109
The Stem Cell Therapeutic and Research Reauthorization Act of 2026 (S. 4109) is a bipartisan bill introduced in the U.S. Senate to continue and enhance federal support for programs that connect patients with life-threatening blood cancers and other diseases to stem cell donors and cord blood units. Specifically, the bill reauthorizes the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory for an additional five years, ensuring the ongoing facilitation of bone marrow and cord blood transplants. The legislation proposes funding of $31,009,000 for the current fiscal year, with an increase to $33,009,000 for each fiscal year from 2027 through 2031. This funding aims to support the collection and management of cord blood units and to improve patient outcomes through continued access to life-saving transplants.